PHOENIX--(BUSINESS WIRE)--Oct 21, 2026--
Carvana (NYSE: CVNA), the industry pioneer for buying and selling cars online, today announced a multi-year renewal of its partnership with Phoenix Rising FC, extending its role as the club's front-of-kit sponsor. Entering their 10th season together, the renewal continues one of the club's longest-standing partnerships and reinforces both organizations' commitment to growing soccer throughout Arizona.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021338700/en/
“Phoenix Rising has been one of our most meaningful hometown partnerships, and we're proud to continue supporting the team as their front-of-kit sponsor,” said Ryan Keeton, Carvana Co-Founder and Chief Brand Officer. “As an Arizona-based company, we know firsthand what this club means to the Valley, and we're excited to keep building on the momentum we've created together since 2018.”
Beyond the professional team, Carvana's commitment extends to Phoenix Rising FC Youth, supporting the development of young players at both the recreational and competitive levels. As the Official Auto Retail Partner of Phoenix Rising FC Youth, Carvana continues to invest in the growth of soccer throughout Arizona, helping create opportunities for the next generation of players. As part of that commitment, the Carvana Corner VIP Suite at Phoenix Rising Stadium will be renovated and expanded to host Carvana Champions of the Match, a program celebrating outstanding members of the Phoenix youth soccer community who are making a positive impact on the game and their communities.
Since the partnership began in 2018, Carvana has supported Phoenix Rising through some of the most significant moments in club history, including its first USL Championship in 2023. The relationship has continued to evolve beyond the professional team, creating meaningful experiences for fans and the broader community, including the recent Special Olympics Field Day, which brought athletes together with Phoenix Rising players and coaches for an inclusive soccer experience.
“Carvana has been part of Phoenix Rising's journey for nearly a decade, and their commitment to our club has gone well beyond what you typically see in a corporate partnership,” said Bobby Dulle, Phoenix Rising FC President. “Their continued investment in both our professional team and youth organization speaks to their belief in the future of soccer in Arizona. We're excited to continue building on what we've accomplished together.”
Additional details on the upcoming season schedule, tickets, and Phoenix Rising home matches will be available in the coming months. For more information, visit phxrisingfc.com.
About Carvana
Carvana’s mission is to change the way people buy and sell cars. Since launching in 2013, more than 4 million customers have chosen Carvana’s leading automotive e-commerce experience to shop, sell, finance, and trade in vehicles entirely online, with the convenience of delivery or local pickup as soon as the same day. Carvana’s unique offering is powered by its passionate team, differentiated national infrastructure, and purpose-built technology.
For more information, please visit Carvana.com.
About Phoenix Rising FC
Phoenix Rising FC is the highest-level professional soccer franchise in Arizona history. Established in 2016, the club won the 2023 USL Championship as well as the 2023, 2020 and 2018 Western Conference Titles. Rising won USL Championship’s 2019 Regular Season Title and holds the record for the longest win streak in American professional soccer history (20 matches). It is owned by legendary Chelsea and Ivory Coast striker, Didier Drogba, Dr. Pablo Prichard, Alex Zheng, Brandon McCarthy, Tim Riester and an impressive collection of local business leaders and international celebrities.
Carvana and Phoenix Rising FC extend partnership entering 10th season together.
IRVINE, Calif.--(BUSINESS WIRE)--Oct 21, 2026--
Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy aging, today announced that it has been selected to receive the Grand Prize in the National Academy of Medicine’s (NAM) Healthy Longevity Global Competition, a global initiative designed to accelerate breakthroughs that extend human healthspan and improve physical, cognitive and social well-being throughout life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021720676/en/
From 2020 to 2025, NAM and its global partners awarded 720 Catalyst Awards totaling more than $36 million to innovators across more than 50 countries and territories. The 2026 Grand Prize was open exclusively to those Catalyst Award recipients and recognizes the groups with the most promising innovation in healthy longevity.
Immunis was recognized for “IMM01-STEM: A First-in-Class Regenerative Biologic Restoring Muscle Function, Metabolism, and Quality of Life in Aging Adults.” The investigational IMM01-STEM therapy is a multi-active biologic that can address the interconnected biological processes underlying age-related muscle and metabolic decline.
Unlike approaches that target a single pathway, IMM01-STEM contains multiple naturally occurring factors designed to act across signaling pathways involved in immune regulation, tissue repair and muscle regeneration. Immunis’ pipeline will investigate IMM01-STEM as both a stand-alone muscle therapy and as an adjunct therapy in combination with GLP-1 therapies to preserve and restore lean mass while enhancing fat loss.
“We are deeply honored to receive this recognition from the National Academy of Medicine,” said Dr. Tom Lane, Chief Science Officer of Immunis. “Healthy longevity is about preserving the strength and function that improve a patient’s quality of life,” said Dr. Lane. “This Grand Prize provides our team with means to continue our clinical research and, eventually, the opportunity to help millions of people.”
Immunis has advanced IMM01-STEM into a randomized Phase 2 clinical trial, with evidence to date demonstrating improvements in measures of muscle function, metabolism and quality of life in aging adults. Blood protein analyses have also identified coordinated changes across immune cell signaling, tissue repair and muscle regeneration pathways. No severe adverse events attributed to IMM01-STEM have been reported to date.
Published preclinical research further supports the therapeutic’s potential, demonstrating improvements across measures including lean mass, fat mass, muscle fiber quality, physical activity, glucose handling and liver health.
The recognition comes as age-related loss of muscle and metabolic function is increasingly emerging as a critical challenge to healthy longevity. By targeting multiple interconnected pathways rather than a single mechanism, Immunis is developing IMM01-STEM with the goal of preserving the strength, mobility and metabolic health that allow people to remain active and independent as they age.
Immunis thanks the National Academy of Medicine for this distinguished honor and celebrates with the other awardees on the culmination of a 7-year long search for the greatest innovations in healthy longevity.
About Immunis
Immunis is a clinical-stage biotechnology company developing first-in-class multi-active biologics designed to restore function lost through aging and disease. Leveraging the body’s innate repair biology, Immunis’ proprietary secretome platform targets multiple pathways simultaneously to improve muscle health, metabolic function, and overall healthspan. The company’s lead investigational therapy, IMM01-STEM, is being evaluated as a potential treatment for sarcopenia and other age-related conditions, with the vision of helping people live healthier, stronger, and more independent lives for longer.
Immunis is the proud winner of the National Academy of Medicine's Healthy Longevity Global Grand Prize Competition
